1332 — Touyun Biotech Income Statement
0.000.00%
Last trade - 00:00- HK$799.59m
- HK$1.25bn
- HK$159.97m
Annual income statement for Touyun Biotech, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 207 | 284 | 316 | 199 | 160 |
| Cost of Revenue | |||||
| Gross Profit | 84.6 | 107 | 120 | 56.6 | 70.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 322 | 389 | 493 | 464 | 238 |
| Operating Profit | -116 | -106 | -178 | -265 | -78.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -172 | -123 | -199 | -273 | -88.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -172 | -124 | -203 | -273 | -88 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -169 | -72.9 | -198 | -269 | -88.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -169 | -72.9 | -198 | -269 | -88.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.061 | -0.021 | -0.07 | -0.077 | -0.031 |